Introduction {#s2}
============

Inspiring dry and cold air during moderate and vigorous physical activity is the key trigger for bronchoconstriction, precipitating dehydration of the airway surface liquid and leading to cell shrinkage and release of inflammatory mediators and airway smooth muscle constriction \[[@C1]\]. This respiratory water loss and resultant airway surface mucosal drying is also thought to lead to both physical and chemical activation of cough receptors \[[@C2]\].

Repeated exercise in the cold is thought to result in a continuous cycle of airway injury and repair, leading to chronically inflamed airways, epithelial damage and cellular airway change \[[@C3]\]. These modifications to airway structure and function appear to underpin the heightened prevalence of exercise-induced bronchoconstriction (EIB) and cough observed in endurance athletes who train and compete in cold and dry environments \[[@C4]\].

It has been known for some time that an increase in the temperature and water content of inspired air can attenuate EIB in asthmatic subjects \[[@C5], [@C6]\]. More recently, B[olger]{.smallcaps} *et al*. \[[@C7]\] demonstrated that EIB in athletes was completely prevented by increasing the temperature and water content of an inspirate from 4°C, 37% relative humidity to 25°C, 94% relative humidity. Post-exercise cough also seems to be more prevalent in environmental conditions that promote airway heat and water loss \[[@C2]\].

One method of increasing the temperature of inspired air and thereby potentially diminishing airway dehydration is to use a facemask that incorporates a heat and moisture exchanger (HME); \[[@C8]--[@C11]\]. An HME mask will warm and humidify inspired air and therefore reduce airway heat and water loss during exercise. This will potentially reduce the incidence of and severity of EIB and may also have the potential to decrease the incidence of cough among athletes engaging in sports in cold dry environments \[[@C12]--[@C14]\]. This is important, given the emphasis placed on nonpharmacological treatment options by patients with asthma. Despite this, to date, international guideline documents \[[@C15]\] indicate that the evidence in support of using HME masks is weak based, on the current availability of only low-quality randomised and noncontrol-based evidence.

The aim of this study was to address this deficiency in the literature by undertaking a randomised SHAM controlled study in asthmatic individuals with EIB, to determine whether an HME facemask can protect against acute bronchoconstriction and, for the first time, post-exercise cough in response to a cycling exercise challenge in a cold, dry environment.

Methods {#s3}
=======

Study population {#s3a}
----------------

This study is registered on ClinicalTrials.gov (identifier: NCT04302610). Following approval from the Faculty of Sciences Research Ethics Advisory Group for Human Participants, University of Kent (0881516) 34 recreationally active participants exercising at least twice per week (6±2 h) provided written informed consent to participate. All participants had a clinician-based diagnosis of asthma; however, participants who did not have a fall in forced expiratory volume in 1 s (FEV~1~) of ≥10% at two consecutive time points following at least one of the exercise challenges (see below) were not included in subsequent analysis (*i.e.* no evidence of EIB).

Participants were excluded if they used an oral corticosteroid daily, were hospitalised due to asthma in the 6 months prior to study commencement and/or had resting FEV~1~\<80% of predicted value \[[@C16]\]. All participants were free from illness in the 2 weeks prior to assessment. Participants were instructed to maintain their usual diet for the duration of the study, to avoid exercise and caffeine for 24 h and 4 h respectively before each visit and arrive at the laboratory at least 2 h post-prandial.

Study design {#s3b}
------------

In a randomised crossover design, participants attended the laboratory on five occasions ([figure 1](#F1){ref-type="fig"}). The visits were as follows: visit 1, peak oxygen uptake (peak *V*′~O~2~~) test on a cycle ergometer; visit 2, familiarisation, and visits 3--5, standardised cycle exercise challenge (EX) in a cold, dry environment. During exercise, participants wore either an HME mask (MASK) (ColdAvenger® expedition balaclava, [www.coldavenger.com](www.coldavenger.com)), a sham mask (SHAM) that was the same HME mask with holes cut across the entire ventilator cup and the ventilator removed ([figure 2](#F2){ref-type="fig"}), or no mask (CONT), wearing only the balaclava to which the mask is attached.

![Flow chart of study design. *V*′~O~2~peak~: peak oxygen uptake; EX: exercise; MASK: heat and moisture exchanger mask; SHAM: sham mask; CONT: no mask.](00271-2019.01){#F1}

![a) Participant wearing the sham mask during exercise. b) Heat and moisture exchanger mask. c) Sham mask.](00271-2019.02){#F2}

The exercise challenges were completed in a randomised order but at the same time of day. The time between each visit was dependant on the participant\'s current medication; participants previously prescribed inhaler medication for asthma/EIB withheld medication prior to each assessment (inhaled corticosteroids (ICSs): 72 h; inhaled long-acting β~2-~agonists (LABAs): 48 h; inhaled short-acting β~2~-agonists (SABAs): the day of the test) \[[@C17]\]. Following each trial, participants had the same amount of time back on their medication before once again stopping treatment before their next exercise. Participants who were not taking any asthma medication, had a minimum of 48 h between trials.

Visit details {#s3c}
-------------

### Visit one {#s3c1}

Cough-specific health status was assessed with the Leicester Cough Questionnaire (LCQ), which is a self-administered 19-item tool (total score range 3--21; with higher scores indicating better health status; \[[@C18]\]). Anthropometric measures were taken and a standardised incremental ramp test to volitional exhaustion was performed to establish peak power on a cycle ergometer (Lode; Corival, Groningen, Netherlands) with simultaneous gas analysis (Cortex Metalyser 3b, CORTEX Biophysik GmbH, Germany). Heart rate was recorded throughout (Polar RS400; Polar Electro Oy, Kempele, Finland) and peak power output was recorded.

### Visit two {#s3c2}

Participants remained on prescribed asthma therapy and completed the exercise protocol as detailed below in a normal lab environment without a mask, as a means of laboratory testing familiarisation.

### Visits three to five {#s3c3}

Participants completed a cough 0--100 mm visual analogue scale (VAS) \[[@C19]\]. Airway inflammation was then assessed prior to each challenge by determining the fraction of exhaled nitric oxide (*F*~eNO~) (NIOX VERO, NIOX, Aerocrine, Sweden) \[[@C20]\]. Resting lung function was then measured by maximal flow-volume spirometry (Spiro-USB and MicroLab, CareFusion, Germany) in accordance with international standards \[[@C21]\]. Maximal flow-volume loops were subsequently measured in duplicate at 3, 5, 7, 10 and 15 min after the challenge, with the highest value at each time point used for analysis. If there was a ≥10% fall in FEV~1~ post-challenge at two consecutive time points, 400 µg inhaled salbutamol was self-administered by the participant and maximal flow loops were repeated 15 min post-administration to ensure that FEV~1~ had returned to within 10% of baseline. The exercise challenges were conducted in an environmental chamber (TIS Services, Hampshire, UK) (8.6±0.9°C, 24.2±4.2% relative humidity) on a cycle ergometer (Lode; Corival, Groningen, Netherlands).

The exercise protocol required participants to complete 3 min of incremental cycling at a work rate of 60, 75 and 90% of their final target power for 1 min at each power output. They then cycled for 6 min at 80% of their peak power (C[rapo]{.smallcaps} *et al*. \[[@C22], [@C23]\]). Heart rate was recorded throughout.

Immediately after exercise, cough frequency was assessed objectively over 24 h with the validated LCM \[[@C24], [@C25]\]. The LCM is an ambulatory system that comprises an MP3 recorder (ICD-PX333, Sony Corporation, Tokyo, Japan), a lapel free-field microphone (LFH9173, Philips, Amsterdam, the Netherlands) and semi-automated cough detection software. Coughs were detected as single events whether they occurred in isolation or in bouts \[[@C25]\]. Cough data were analysed *via* cough detection software based on the hidden Markov model as described previously \[[@C25]\]. Participants completed an additional VAS 24 h after exercise.

Statistical analysis {#s3d}
--------------------

Data are presented as mean±[sd]{.smallcaps} unless otherwise stated. Shapiro--Wilk tests were used to test for normal distribution. Differences between the three exercise conditions were examined using repeated-measures ANOVA. Where data were not normally distributed, Friedman\'s test was used with *post hoc* pairwise comparisons where appropriate. Spearman\'s rank correlation coefficient was used to investigate the relationship between VAS score and cough per hour, percentage fall in FEV~1~ and coughs per hour after exercise or LCQ score and cough count. All analysis was conducted using SPSS software, v.23 (SPSS, IBM, Armonk, NY, USA) with significance accepted at p\<0.05.

Results {#s4}
=======

Thirty-four recreationally active participants were initially enrolled in the study. Two participants were lost to subsequent follow-up following the peak *V*′~O~2~~ trial (three following the familiarisation and two following the initial exercise). One participant was excluded due to impaired resting lung function (FEV~1~\<70% predicted at baseline). The remaining 26 participants (20 males, 6 females, aged 27.6±9.2 years, height: 172.7±7.3 cm, mass: 71.2±12.8 kg, exercising: 5.8±2.2 h per week, peak *V*′~O~2~~: 42.8±8.2 mL·kg^−1^·min^−1^). Seventeen patients were prescribed inhaler therapy for their asthma (seven ICSs, four, combined ICSs and LABAs and eight SABAs as required). Eleven of the 26 participants however, failed to demonstrate a fall \<10% in FEV~1~ after exercise in any of the trials (range, 4 to −9%) and thus we were unable to confirm definite evidence of asthma/EIB. Of these, three had a history of EIB only, three were currently using ICSs, two were using a combination inhaler, two were using only SABAs and four were using no therapy. Subsequent analysis was thus only undertaken using the participants (12 males, 3 females) with confirmatory evidence of EIB ([table 1](#TB1){ref-type="table"}).

###### 

Participant characteristics, peak oxygen uptake (*V*′~O~2~~) and baseline respiratory assessment data (while using current medication) (n=15)

                            **Measured**   **Percentage of predicted**
  ------------------------- -------------- -----------------------------
  **Age years**             29.3±9.2       \-
  **Height cm**             172.2±8.1      \-
  **Weight kg**             73.4±14.0      \-
  **Peak *V*′~O~2~~**       43.26±8.11     \-
  **Peak power output W**   246.3±42.7     \-
  **FEV~1~ L**              3.57±0.64      93.7±9.0
  **FVC L**                 4.67±0.87      103.7±11.1
  **PEF L·min^−1^**         536±93         99.3±11.0
  **FEV~1~/FVC**            76.7±8.8       93.9±10.2

Data are presented as mean±SD. FEV~1~: forced expiratory volume in 1 s; FVC: forced vital capacity; PEF: peak expiratory flow.

Exercise trials {#s4a}
---------------

Descriptive data for lung function pre and post-challenge can be seen in [table 2](#TB2){ref-type="table"}. The percentage fall in FEV~1~ following the CONT exercise was significantly greater than that of MASK (p\<0.01), with all but one participant demonstrating a greater fall in FEV~1~ following CONT than MASK ([figure 3](#F3){ref-type="fig"}). Ten out of 15 participants also had a greater drop in SHAM than MASK ([figure 3](#F3){ref-type="fig"}); however, SHAM was not significantly different from either MASK (p=0.17) or CONT (p=0.51).

###### 

Lung function pre and post-challenge (n=15)

                                                     **MASK**     **SHAM**         **CONT**     **p-value**                                      
  -------------------------------------------------- ------------ ---------------- ------------ -------------- ------------ ------------- ------ ------------
  ***F*~eNO~ ppb**                                   39 (33)      \-               42 (33)      \-             38 (51)      \-            0.88   \-
  **FEV~1~ L**                                       3.52±0.58    3.19±0.62^¶^     3.51±0.58    3.08±0.57      3.53±0.61    2.99±0.62     0.76   \<0.01
  **FVC L**                                          4.68±0.81    4.45±0.74^¶^     4.65±0.83    4.36±0.73      4.64±0.80    4.32±0.72     0.62   0.03
  **PEF L·min^−1^**                                  536±81       499±86^¶^        531±80       487±88         533±89       471±92        0.57   \<0.01
  **FEV~1~/FVC**                                     75.60±9.26   71.67±10.87^¶^   75.67±8.82   70.80±11.86    76.33±9.77   69.20±10.97   0.59   0.03
  **Maximal change in FEV~1~ after challenge (%)**   \-           −6.0 (7.0)^¶^    \-           −11.0 (11.0)   \-           −13.0 (9.0)   \-     \<0.01^\#^

Data for maximal percentage change in FEV~1~ and *F*~eNO~ were not normally distributed and therefore were analysed with Friedman\'s tests and presented as the median score (interquartile range). Other data are presented as mean±SD, unless otherwise stated. MASK: heat and moisture exchanger mask; SHAM: sham mask; CONT: no mask; *F*~eNO~: exhaled nitric oxide fraction; FEV~1~: forced expiratory volume in 1 s; FVC: forced vital capacity; PEF: peak expiratory flow. ^\#^: significant difference (p\<0.05) between exercise condition; ^¶^: significant difference (p\<0.05) *versus* CONT.

![Maximum percentage fall from baseline in forced expiratory volume in 1 s (FEV~1~) after exercise challenge. MASK: heat and moisture exchanger mask; SHAM: sham mask; CONT: no mask. \*: significant difference (p\<0.05) *versus* CONT. Dashed line represents the threshold for a positive challenge.](00271-2019.03){#F3}

Cough {#s4b}
-----

One participant did not participate in cough monitoring due to their occupation. Four of the remaining 14 participants (29%) reported cough as a problematic symptom following exercise.

The LCQ showed all but one participant scored either a 6 (hardly any of the time) or 7 (none of the time) in all domains (physical, psychological and social) regarding the impact that cough had upon the different aspects of their lives. The remaining participant scored 5 (a little of the time) for all domains. No difference was seen in LCQ total score between those who reported cough as a troublesome symptom (median, 19; IQR, 3) and those who did not (median, 20; IQR, 2).

Baseline cough VAS score was 9±7 mm out of 100 mm, with a range of 1 to 19 mm. No differences were seen between exercise trials in cough count per hour over 24 h ([figure 4](#F4){ref-type="fig"}), number of coughs recorded in the first hour following exercise or participants self-report of cough 24 h after exercise trial using VAS ([table 3](#TB3){ref-type="table"}).

![Coughs per hour over a 24-h monitoring period. MASK: heat and moisture exchanger mask; SHAM: sham mask; CONT: no mask.](00271-2019.04){#F4}

###### 

Cough results (n=13)

                                                      **MASK**   **SHAM**   **CONT**   **p-value**
  --------------------------------------------------- ---------- ---------- ---------- -------------
  **Number of coughs per hour**                       3 (3)      2 (3)      3 (3)      0.06
  **Number of coughs in first hour after exercise**   17 (17)    15 (17)    8 (24)     0.92
  **VAS 24-h after exercise mm (n=15)**               7 (24)     14 (27)    10 (24)    0.52

Data were not normally distributed and therefore were analysed with Friedman\'s test and presented as the median score (interquartile range). MASK: heat and moisture exchanger mask; SHAM: sham mask; CONT: no mask. VAS: 0--100 mm visual analogue scale.

There was no difference between those who reported cough as a troublesome symptom and those who did not in the number of coughs in the first hour (n=14, yes cough: 18±14, no cough: 13±13, p=0.56) or cough per hour in the 24-h monitoring period (n=14, yes cough: 2±2, no cough: 3±2, p=0.88), in the familiarisation visit or any of the experimental conditions.

Spearman\'s rank correlation coefficient demonstrated no relationship between VAS score and cough per hour, percentage fall in FEV~1~ and coughs per hour after exercise or LCQ score and cough count following the familiarisation trial.

Discussion {#s5}
==========

This study demonstrates that wearing an HME mask during a cycle exercise challenge in a cold, dry environment results in an attenuation in EIB severity when compared with not wearing a mask. Only, a third of participants with EIB demonstrated evidence of EIB (≥10% fall in FEV~1~ after exercise) while wearing a mask, compared to 87% with no mask.

The results from the present study are in agreement with earlier studies: S[tewart]{.smallcaps} *et al*. \[[@C12]\] concluded that their facemask retained heat and moisture and effectively controlled EIB in most patients following exercise at 80% predicted HR~max~. They noted that wearing the mask decreased the post-exercise drop in FEV~1~ by 9%. The mask in our study was more effective in controlling EIB; however, without the mask, their patients exhibited a larger range in EIB severity (FEV~1~ fall post-exercise between 18 to 52%). Similarly, N[isar]{.smallcaps} *et al*. \[[@C11]\] demonstrated that wearing an active mask during a 6-min cycle challenge inhaling a cold air supply (−13°C) reduced the post-exercise fall in FEV~1~ to −10% compared to −22% with a control mask.

Previous studies have also compared HME masks to pre-treatment with a bronchodilator and found that they were equally effective in attenuating a drop in lung function \[[@C8], [@C10]\]. B[euther and]{.smallcaps} M[artin]{.smallcaps} \[[@C8]\] reported that following 10 min running at 85% HRmax, breathing cold medical grade air (−15 to −25°C), FEV~1~ fell 28% with a placebo mask, 6% with an active mask, and 11% with pre-treatment with albuterol. Furthermore, combining the use of inhaled β~2~-agonists prior to exercise with an HME mask may completely preserve lung function \[[@C10]\]. A benefit to this strategy may be that it can provide complete control against various mechanisms underlying EIB. Future investigations could investigate the long-term impact of using inhaler therapy and HME in combination to protect against EIB and maintain airway health.

Acute exercise in cold, dry environments increases the risk of developing EIB \[[@C6]\]. It has been suggested that the use of β~2~-agonists may make it possible for more cold, dry air to reach the lower airways. Although the β~2~-agonists will acutely reduce bronchoconstriction, they may in the end cause more injury to the mucosa \[[@C10]\]. This combined with the effectiveness of the HME mask suggests that there may be value in encouraging all individuals exercising in cold, dry environments who are susceptible to EIB, to wear an HME mask where practical, whether they are using medication or not. Another potential benefit of using an HME for the prevention of EIB is that it has the potential to reduce the level of β~2~-agonists that athletes use prophylactically, which would be beneficial as there is the potential for the development of tachyphylaxis and a potential desensitisation of repeat dosing \[[@C26]\].

As a group, our participants demonstrated a benefit to wearing the HME mask when compared with a control condition. However, two of our participants did not appear to respond to wearing the HME mask. These participants had the most severe EIB of the group. It is not clear whether this was related to EIB severity or phenotype as it was not feasible to conduct a subanalysis between mild and moderate EIB participants due to relatively small number of participants in each severity classification. We encourage future research to investigate the differences in response to HME masks between EIB severity and phenotype.

This was the first study to attempt to measure objective and subjective measures of cough following exercise in participants with EIB. Recently, the LCM has proven useful in objectively assessing cough in asthma management \[[@C27]\] and an alternative automated device has also been found capable of increasing patient awareness of the patterns of cough for early detection of worsening asthma \[[@C28]\]. These studies show that cough monitoring has great potential for assessing the response to asthma therapy. Results from this study however, showed no differences in cough frequency following exercise between trials for either cough per hour over the 24-h monitoring period, or more acutely in the hour after exercise. In addition, no differences were seen in the participant\'s perception of cough, as indicated by VAS. This however, is unsurprising because the relationship between objective cough frequency and subjective measures of cough such as VAS has been shown to be mild to moderate \[[@C24]\]. Furthermore, as per guidelines \[[@C15]\] we adhered to restricting ICSs for 72 h but it is possible that a longer (*i.e.* \>2 weeks) ICS washout may result in a higher background coughing frequency.

Surprisingly, only four participants in this study reported cough as a troublesome symptom following exercise. It may be that cough frequency in the current cohort was too small to observe any change. Low levels of cough were unexpected, given that cough is the most commonly reported respiratory symptom by athletes \[[@C29]\]. Participants in this study were recreational rather than elite athletes so this may go some way to explain this observation. The environment we subjected our participants to may also have not been provocative enough to induce cough. A recent study demonstrated that 68% of participants who exercised at −20°C experienced significant cough, which was significantly attenuated when participants exercised wearing an HME mask \[[@C14]\].

A prior power calculation indicated that we needed to recruit 34 participants with EIB. Despite recruiting 34 participants, the final number reduced by 55% due to participant withdrawal and others failing to demonstrate evidence of EIB during the trials. All participants had a physician\'s diagnosis of asthma, and the majority were taking prescribed medication; however, 11 out of 26 (42%) demonstrated no evidence of EIB during the trial. This is an important issue by itself and is in support of the study in which A[aron]{.smallcaps} *et al*. \[[@C30]\] found that in 33.1% of adults with physician-diagnosed asthma, evidence of asthma could not be established. This highlights that objective testing should be utilised more frequently in the diagnosis and follow-up of asthma patients.

Furthermore, this impacted on the power of the study and under-recruiting participants with EIB may be the reason that there was no statistical difference between the HME mask and SHAM conditions. However, the difference between the HME mask and SHAM fall in FEV~1~ was 5%, which may be clinically meaningful, especially as the mask reduced the mean fall below the 10% fall criterion to demonstrate EIB. Many of the earlier studies only included the use of either a sham or a no mask trial, and we felt it was important to include both. There may also be the possibility that the SHAM still provided some warming and humidification to the inspired air, and therefore offered some protection. Indeed, an earlier study demonstrated partial attenuation of EIB when individuals exercised in cold environments and covered their mouth with a scarf \[[@C31]\]. Therefore, it may be beneficial for athletes who may not want to wear an actual mask to cover their nose and mouth with a scarf or snood during training and competing in cold environments.

As seen in [figure 2](#F2){ref-type="fig"}, to wear the mask we used it needs to be attached to a balaclava. Participants reported that they became very hot even in a short exercise bout, which would potentially be a barrier to athletes wearing the mask during training. Future investigations may look to develop a heat and moisture mask that is more practical to wear in UK weather or investigate whether similar benefits can be achieved through using an everyday scarf to cover the mouth during exercise.

In conclusion, HME masks can attenuate bronchoconstriction in individuals with asthma/EIB when exercising in cold, dry environments. Developments in mask design should look to make the masks less intrusive on the individual so that they are more likely to wear them during exercise in dry and cold environments.
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